USD10
FBRX Shares
About Forte BiosciencesForte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
USD10
FBRX Shares
About Forte BiosciencesForte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Stats
TRADING WINDOW
Closed
OPENS AT
Jun 4 at 1:30 PM GMT+0
MARKET CAP
$339.95M
OPEN PRICE
Not enough data
LOW (1Y)
$9.10
HIGH (1Y)
$35.80
LOW (24H)
$16.60
HIGH (24H)
$18.59
VOLUME (24H)
$204.07K
6.79%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $17.90 | |
1 Week | $20.95 | |
1 Month | $29.04 | |
1 Year | $10.35 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
